• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aligos Therapeutics Inc.

    8/6/25 4:36:50 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALGS alert in real time by email
    S-8 1 d25818ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 6, 2025

    Registration No. 333-  

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Aligos Therapeutics, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   82-4724808

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    One Corporate Dr., 2nd Floor

    South San Francisco, California

      94080
    (Address of Principal Executive Offices)   (Zip Code)

    2020 Incentive Award Plan

    (Full Title of the Plan)

    Lawrence M. Blatt, Ph.D.

    President and Chief Executive Officer

    Aligos Therapeutics, Inc.

    One Corporate Dr., 2nd Floor

    South San Francisco, California 94080

    (800) 466-6059

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Mark V. Roeder

    John C. Williams

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    (650) 328-4600

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    Proposed sale to take place as soon after the effective date of the

    registration statement as awards under the plans are exercised and/or vest.

     

     
     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this Registration Statement, Aligos Therapeutics, Inc. is sometimes referred to as “Registrant”.

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

    This Registration Statement on Form S-8 is filed by the Registrant, relating to 1,000,000 shares of its common stock, $0.0001 par value (the “Common Stock”), issuable to eligible employees, directors and consultants of the Registrant under the Registrant’s 2020 Incentive Award Plan, as amended (the “2020 Plan”). Shares available for issuance under the 2020 Plan were previously registered on registration statements on Form S-8 filed with the Commission on October 20, 2020, Registration No. 333-249568, March  23, 2021, Registration No. 333-254628, March 10, 2022, Registration No. 333-263447, March 9, 2023, Registration No. 333-270417, March 12, 2024, Registration No. 333-277860, and March 10, 2025, Registration No. 333-285677 (collectively, the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with Section E of the General Instructions to Form S-8 regarding Registration of Additional Securities. Pursuant to Section E of the General Instructions to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    Item 3. Incorporation of Documents by Reference.

    The following documents filed with the Commission by the Registrant are incorporated by reference in this Registration Statement:

     

      •  

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 10, 2025;

     

      •  

    the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March  10, 2025, from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 28, 2025;

     

      •  

    the Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on May  6, 2025 and August 6, 2025;

     

      •  

    the Registrant’s Current Reports on Form 8-K filed with the Commission on February  3, 2025, February 12, 2025 (solely with respect to Items 1.01, 3.02 and Exhibits 4.1, 4.2, 10.1, 10.2, 10.3, 10.4 and 104 thereto) and June 26, 2025; and

     

      •  

    the description of the Registrant’s Common Stock which is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in the Registrant’s registration statement on Form 8-A , filed on October 13, 2020, as updated by the description of the Registrant’s Common Stock contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 10, 2025, including any amendments or reports filed for the purposes of updating such description.


    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 8. Exhibits.

     

    Exhibit

    Number

           Incorporated by Reference    

    Filed

    Herewith

     
      Exhibit Description    Form      Date      Number        
     4.1(a)   Amended and Restated Certificate of Incorporation.      8-K        10/20/2020        3.1    
     4.1(b)   Certificate of Amendment to Amended and Restated Certificate of Incorporation.      8-K        6/28/2024        3.1    
     4.1(c)   Certificate of Amendment to Amended and Restated Certificate of Incorporation.      8-K        8/19/2024        3.1    
     4.1(d)   Certificate of Amendment to Amended and Restated Certificate of Incorporation.      8-K        6/26/2025        3.1    
     4.2   Amended and Restated Bylaws.      8-K        10/20/2020        3.2    
     4.3   Form of Common Stock Certificate.      10-Q        11/6/2024        4.2    
     4.4   Form of 2023 Pre-Funded Warrant.      8-K        10/25/2023        4.1    
     4.5   Form of 2023 Common Warrant.      8-K        10/25/2023        4.2    
     4.6   Form of 2025 Pre-Funded Warrant.      8-K        2/12/2025        4.1    
     4.7   Form of 2025 Common Warrant.      8-K        2/12/2025        4.2    
     5.1   Opinion of Latham & Watkins LLP.              X  
    23.1   Consent of Latham & Watkins LLP (included in Exhibit 5.1).              X  
    23.2   Consent of Independent Registered Public Accounting Firm.              X  
    24.1   Power of Attorney (included on signature page).              X  
    99.1(a)#   2020 Incentive Award Plan.      S-1/A        10/9/2020        10.6 (a)   
    99.1(b)#   Amendment to 2020 Incentive Award Plan.      8-K        6/28/2024        10.1    
    99.1(c)#   Amendment to 2020 Incentive Award Plan.      8-K        6/26/2025        10.1    
    107.1   Registration Fee Table.              X  

     

    #

    Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this August 6, 2025.

     

    Aligos Therapeutics, Inc.
    By:  

    /s/ Lawrence M. Blatt

      Lawrence M. Blatt, Ph.D.
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Lawrence M. Blatt, Ph.D. and Lesley Ann Calhoun, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.


    Signature    Title    Date

    /s/ Lawrence M. Blatt

    Lawrence M. Blatt, Ph.D.

      

    President, Chief Executive Officer and Chairman

    (Principal Executive Officer)

       August 6, 2025

    /s/ Lesley Ann Calhoun

    Lesley Ann Calhoun

      

    Executive Vice President, Chief Operating Officer and Chief Financial Officer

    (Principal Financial and Accounting Officer)

       August 6, 2025

    /s/ K. Peter Hirth

    K. Peter Hirth, Ph.D.

       Director    August 6, 2025

    /s/ Bridget Martell

       Director    August 6, 2025
    Bridget Martell, M.A., M.D.      

    /s/ Carole Nuechterlein

    Carole Nuechterlein

       Director    August 6, 2025

    /s/ James Scopa

    James Scopa

       Director    August 6, 2025

    /s/ Heather Preston

    Heather Preston, M.D.

       Director    August 6, 2025

    /s/ Margarita Chavez

    Margarita Chavez

       Director    August 6, 2025

     

    Get the next $ALGS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGS

    DatePrice TargetRatingAnalyst
    8/18/2025$50.00Buy
    H.C. Wainwright
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    3/11/2022$47.00 → $15.00Overweight
    Piper Sandler
    3/11/2022$10.00 → $11.00Outperform
    SVB Leerink
    2/16/2022$15.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $ALGS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

    SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    8/14/25 11:54:19 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Aligos Therapeutics Inc.

    SCHEDULE 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)

    8/13/25 2:00:06 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

    SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    8/12/25 9:00:35 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company's stock (the "Inducement Grant") to newly hired employees on August 12, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducem

    8/15/25 8:30:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

    SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection. "Despite available treatments for chronic HBV infection, better therapies are needed to stem the progression to end-stage liver disease and liver cancer," said Nezam Afdhal, MD, DSc, Chief of Gastroenterology, Hepatology, and Nutrition at Beth Israel Deacone

    8/13/25 8:30:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025. "Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory approvals across a number of countries, including the US, China, Canada, Taiwan, UK, New Zealand, and Moldova," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "Site activations are in progress, subj

    8/6/25 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Blatt Lawrence

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 5:14:30 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Symons Julian A.

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 5:14:05 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Calhoun Lesley Ann

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 4:41:45 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aligos Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00

    8/19/24 6:51:07 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously

    1/6/23 9:05:04 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

    SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. "I am pleased to welcome Kieron to Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "With decades of experience, Kieron's extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters."

    6/18/25 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

    SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. "I am thrilled to welcome Laura to the Aligos team," said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos. "Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expe

    5/20/25 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Appoints David Perry as Vice President of Business Development

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. "We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline

    10/1/24 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Financials

    Live finance-specific insights

    View All

    Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

    ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig

    9/19/24 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th

    9/18/24 5:00:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

    CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient

    3/10/22 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:57:50 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:19:11 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 5:03:16 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care